PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Noberini, Roberta ^a   Mitra, Sayantan ^a,f   Salvucci, Ombretta ^b   Valencia, Fatima ^a   Duggineni, Srinivas ^c   Prigozhina, Natalie ^a,d   Wei, Ke ^a   Tosato, Giovanna ^b   Huang, Ziwei ^c   Pasquale, Elena B ^a,e  

^a BURNHAM INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d UNIVERSITY OF SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CLONTECH Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR B4; MACROGOL; PROTEIN INHIBITOR; THREONYLASPARAGINYLTYROSINYLLEUCYLPHENYLALANYLSERYLPROLYLASPARAGINYLGLYCYLPROLYLISOLEUCYLALANYLARGINYLALANYLTRYPTOPHAN; UNCLASSIFIED DRUG; EPHRIN B2; MACROGOL DERIVATIVE; PEPTIDE; PHOSPHOTYROSINE; TNYL RAW PEPTIDE; TNYL-RAW PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TARGETING; EMBRYO; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; ANGIOGENESIS; ANIMAL; BLOOD; CELL LINE; CHEMISTRY; COCULTURE; CULTURE MEDIUM; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; HALF LIFE TIME; METABOLISM; PERICARDIUM; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STABILITY; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL LINE; COCULTURE TECHNIQUES; CULTURE MEDIA; EPHRIN-B2; EPITHELIAL CELLS; HALF-LIFE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICROCHEMISTRY; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PERICARDIUM; PHOSPHORYLATION; PHOSPHOTYROSINE; POLYETHYLENE GLYCOLS; PROTEIN BINDING; PROTEIN STABILITY; RECEPTOR, EPHB4;

EID: 83355173217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028611     Document Type: Article

References (72)

1. Pasquale EB, (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
2. Noren NK, Pasquale EB, (2007) Paradoxes of the EphB4 receptor in cancer. Cancer Res 67: 3994-3997.
3. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, et al. (2007) The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96: 1083-1091.
4. Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, et al. (2009) Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69: 3736-3745.
5. Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, et al. (2006) EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25: 769-780.
6. Xia G, Kumar SR, Masood R, Koss M, Templeman C, et al. (2005) Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance. Clin Cancer Res 11: 4305-4315.
7. Batlle E, Bacani J, Begthel H, Jonkeer S, Gregorieff A, et al. (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435: 1126-1130.
8. Heroult M, Schaffner F, Pfaff D, Prahst C, Kirmse R, et al. (2010) EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinb2. Mol Cancer Res 8: 1297-1309.
9. Meyer S, Hafner C, Guba M, Flegel S, Geissler EK, et al. (2005) Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol 27: 1197-1206.
10. Yang NY, Pasquale EB, Owen LB, Ethell IM, (2006) The EphB4 Receptor-tyrosine Kinase Promotes the Migration of Melanoma Cells through Rho-mediated Actin Cytoskeleton Reorganization. J Biol Chem 281: 32574-32586.
11. Yang NY, Lopez-Bergami P, Goydos JS, Yip D, Walker AM, et al. (2010) The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand. Pigment Cell Melanoma Res 23: 684-687.
12. Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, et al. (2009) The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res 69: 7430-7438.
13. Heroult M, Schaffner F, Augustin HG, (2006) Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312: 642-650.
14. Kuijper S, Turner CJ, Adams RH, (2007) Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc Med 17: 145-151.
15. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB, (2004) Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 101: 5583-5588.
16. Fuller T, Korff T, Kilian A, Dandekar G, Augustin HG, (2003) Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 116: 2461-2470.
17. Steinle JJ, Meininger CJ, Chowdhury U, Wu G, Granger HJ, (2003) Role of ephrin B2 in human retinal endothelial cell proliferation and migration. Cell Signal 15: 1011-1017.
18. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, et al. (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465: 487-491.
19. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, et al. (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465: 483-486.
20. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, et al. (2006) Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 124: 161-173.
21. Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S, et al. (2009) EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 114: 1707-1716.
22. Erber R, Eichelsbacher U, Powajbo V, Korn T, Djonov V, et al. (2006) EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. Embo J 25: 628-641.
23. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, et al. (2010) Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol 176: 2029-2038.
24. Martiny-Baron G, Holzer P, Billy E, Schnell C, Brueggen J, et al. (2010) The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis 13: 259-267.
25. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, et al. (2006) Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4: 111-121.
26. Chen K, Bai H, Arzigian M, Gao YX, Bao J, et al. (2010) Endothelial cells regulate cardiomyocyte development from embryonic stem cells. J Cell Biochem 111: 29-39.
27. Wang Z, Cohen K, Shao Y, Mole P, Dombkowski D, et al. (2004) Ephrin receptor, EphB4, regulates ES cell differentiation of primitive mammalian hemangioblasts, blood, cardiomyocytes, and blood vessels. Blood 103: 100-109.
28. Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, et al. (2004) Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 6: 248-257.
29. Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, et al. (2006) The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 107: 2330-2338.
30. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, et al. (2010) Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 10: 641.
31. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, et al. (2009) The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113: 254-263.
32. Ehlken C, Martin G, Lange C, Gogaki EG, Fiedler U, et al. (2011) Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy. Acta Ophthalmol 89: 82-90.
33. Koolpe M, Burgess R, Dail M, Pasquale EB, (2005) EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 280: 17301-17311.
34. Xiong C, Huang M, Zhang R, Song S, Lu W, et al. (2011) In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide. J Nucl Med 52: 241-248.
35. Chrencik JE, Brooun A, Recht MI, Kraus ML, Koolpe M, et al. (2006) Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 14: 321-330.
36. Salvucci O, de la Luz Sierra M, Martina JA, McCormick PJ, Tosato G, (2006) EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood 108: 2914-2922.
37. Bochenek ML, Dickinson S, Astin JW, Adams RH, Nobes CD, (2010) Ephrin-B2 regulates endothelial cell morphology and motility independently of Eph-receptor binding. J Cell Sci 123: 1235-1246.
38. Olsen JV, Ong SE, Mann M, (2004) Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol Cell Proteomics 3: 608-614.
39. Jazayeri JA, Carroll GJ, (2008) Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 22: 11-26.
40. McGregor DP, (2008) Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 8: 616-619.
41. Meyer DL, Schultz J, Lin Y, Henry A, Sanderson J, et al. (2001) Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci 10: 491-503.
42. Lee HJ, Pardridge WM, (2001) Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug Chem 12: 995-999.
43. Werle M, Bernkop-Schnurch A, (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30: 351-367.
44. Eid H, Larson DM, Springhorn JP, Attawia MA, Nayak RC, et al. (1992) Role of epicardial mesothelial cells in the modification of phenotype and function of adult rat ventricular myocytes in primary coculture. Circ Res 71: 40-50.
45. Wada AM, Smith TK, Osler ME, Reese DE, Bader DM, (2003) Epicardial/Mesothelial cell line retains vasculogenic potential of embryonic epicardium. Circ Res 92: 525-531.
46. Prigozhina NL, Heisel A, Wei K, Noberini R, Hunder EA, et al. (2011) Characterization of a novel angiogenic model based on stable, fluorescently labeled endothelial cell lines and suitable for high content screening. Biol Cell 103: 467-81.
47. Ladner RC, Sato AK, Gorzelany J, de Souza M, (2004) Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 9: 525-529.
48. Torchilin VP, Lukyanov AN, (2003) Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8: 259-266.
49. Zhang R, Xiong C, Huang M, Zhou M, Huang Q, et al. (2011) Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials 32: 5872-5879.
50. Galati R, Verdina A, Falasca G, Chersi A, (2003) Increased resistance of peptides to serum proteases by modification of their amino groups. Z Naturforsch C 58: 558-561.
51. Oliner J, Min H, Leal J, Yu D, Rao S, et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516.
52. Harris JM, Chess RB, (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221.
53. Jevsevar S, Kunstelj M, Porekar VG, (2010) PEGylation of therapeutic proteins. Biotechnol J 5: 113-128.
54. Veronese FM, Pasut G, (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10: 1451-1458.
55. Pasut G, Veronese FM, (2009) PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 61: 1177-1188.
56. Joralemon MJ, McRae S, Emrick T, (2010) PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun (Camb) 46: 1377-1393.
57. Veronese FM, Mero A, (2008) The impact of PEGylation on biological therapies. BioDrugs 22: 315-329.
58. Kang JS, Deluca PP, Lee KC, (2009) Emerging PEGylated drugs. Expert Opin Emerg Drugs 14: 363-380.
59. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, et al. (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 6043-6052.
60. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, et al. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000.
61. Tigges U, Hyer EG, Scharf J, Stallcup WB, (2008) FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development 135: 523-532.
62. Ribatti D, Nico B, Crivellato E, (2011) The role of pericytes in angiogenesis. Int J Dev Biol 55: 261-268.
63. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E, (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165.
64. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M, (1999) In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59: 5012-5016.
65. Huang J, Soffer SZ, Kim ES, McCrudden KW, New T, et al. (2004) Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2: 36-42.
66. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
67. Noren NK, Yang NY, Silldorff M, Mutyala R, Pasquale EB, (2009) Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. Biochem J 422: 433-442.
68. Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, et al. (2010) Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 49: 6687-6695.
69. Menzel P, Valencia F, Godement P, Dodelet VC, Pasquale EB, (2001) Ephrin-A6, a new ligand for EphA receptors in the developing visual system. Developmental Biology 230: 74-88.
70. Adams RH, Diella F, Hennig S, Helmbacher F, Deutsch U, et al. (2001) The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 104: 57-69.
71. Flanagan JG, Cheng HJ, Feldheim DA, Hattori M, Lu Q, et al. (2000) Alkaline phosphatase fusions of ligands or receptors as in situ probes for staining of cells, tissues, and embryos. Methods in Enzymology 327: 19-35.
72. Korff T, Augustin HG, (1999) Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112 (Pt 19): 3249-3258.